Cyprus Mail
Health

Drug shown to delay spread of prostrate cancer

Prostate cancer is the leading cancer affecting men

German drugmaker Bayer and Finland’s Orion said on Wednesday a study showed a prostate cancer drug they are jointly developing can delay the spread of the disease to other parts of the body.

A study on men with non-metastatic prostate cancer that could not be helped with hormonal therapy met the primary goal of showing oral drug darolutamide can delay the spread of metastases, the companies said in a statement.

Shares in Orion, which sold certain rights to the drug in a collaboration deal with Bayer in 2014, were up 7.5 percent at 0740 GMT, while Bayer’s shares were down 0.8 percent.

Full details of the trials will be presented at a medical conference, Bayer said.

Bayer added it would now speak to health authorities about a possible request for marketing approval of darolutamide, a compound that was granted “fast track” designation by the U.S. Food and Drug Administration in the prostate cancer setting, potentially speeding the approval process.

Bayer shares slumped on Tuesday after a U.S. judge affirmed a verdict against its Monsanto unit that found glyphosate-based weedkillers responsible for a man’s terminal cancer.

Related Posts

Bird flu identified at two locations in Famagusta area, poultry owners warned to be alert

Kyriacos Nicolaou

Researchers test mRNA technology for universal flu vaccine

Reuters News Service

Okypy expects small surplus next year, MPs told

Elias Hazou

Measles now an imminent global threat due to pandemic

Reuters News Service

Two new functions added to users’ Gesy system

Nikolaos Prakas

World Cup gatherings may fuel Brazil’s latest COVID wave

Reuters News Service